Zoladex 3
Sponsors
UZ Leuven, Grupo Espanol De Investigacion En Cancer De Mama, Astrazeneca AB, Instituto De Investigacion En Oncología Radioterapica FEOR, Fundacion Grupo Espanol De Investigacion En Cancer De Mama
Conditions
Early Breast CancerOligorecurrent hormone-sensitive prostate cancer patientsPatients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)Patients with invasive breast cancer in early stagesProstate Cancer
Phase 1
Phase 3
Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.
RecruitingCTIS2022-502373-42-00
Start: 2022-04-25Target: 873Updated: 2025-03-31
Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial
RecruitingCTIS2024-517666-41-00
Start: 2023-03-13Target: 534Updated: 2026-01-14
Phase 4
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES
RecruitingCTIS2022-502706-33-00
Start: 2018-01-10Target: 8000Updated: 2025-07-16
Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study"
Not yet recruitingCTIS2025-522848-40-00
Target: 74Updated: 2025-12-29